Nordson Corporation (NDSN) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended July 31, 2025, and the nine months ended July 31, 2025. Nordson Corporation is a precision technology company manufacturing products for dispensing, applying, and controlling fluids, as well as medical devices. The company operates through three segments: Industrial Precision Solutions (IPS), Medical and Fluid Solutions (MFS), and Advanced Technology Solutions (ATS).
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Sales | $741.5 million | $661.6 million | $2,039.9 million | $1,945.4 million |
| Operating Profit | $187.8 million | $167.1 million | $497.5 million | $495.1 million |
| Net Income | $125.8 million | $117.3 million | $332.8 million | $345.1 million |
| Diluted EPS | $2.22 | $2.04 | $5.83 | $5.99 |
| Operating Margin | 25.3% | 25.3% | 24.4% | 25.4% |
| Effective Tax Rate | 21.0% | 21.5% | 19.7% | 21.1% |
| Cash from Operations (YTD) | $516.3 million | $459.8 million | ||
| Total Debt (Long-term + Current) | $2,129.1 million | $2,223.9 million | ||
| Cash & Equivalents | $147.8 million | $115.7 million (Oct 31, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Q3 sales increased 12.1% year-over-year, driven by a 31.6% increase in the MFS segment (largely due to the Atrion acquisition) and a 17.4% increase in ATS. IPS sales were flat (0.5% increase).
- Divestiture Charges: The company recorded $12.2 million in divestiture and related charges in Q3 2025, primarily associated with the exit of its medical contract manufacturing business. This included a $4.7 million impairment charge and a $7.5 million facility closure charge.
- Interest Expense: Interest expense rose 39.6% in Q3 and 31.5% YTD compared to the prior year, attributed to higher average debt levels from recent acquisitions.
- Segment Performance:
- IPS: Organic sales declined 2.0% in Q3 due to weaker polymer processing demand.
- MFS: Organic sales were flat (-0.4%) including the held-for-sale business; excluding that business, organic sales grew 4%.
- ATS: Organic sales grew 14.6% in Q3, driven by electronics dispense products.
Guidance, Outlook, and Risks
- Acquisitions & Divestitures: The company completed the acquisition of Atrion Corporation in August 2024. In Q3 2025, it entered a definitive agreement to sell select product lines in its medical contract manufacturing business, expected to close in Q4 2025.
- Capital Allocation: The company continues an aggressive share repurchase program. In Q3 2025, it repurchased approximately 336,000 shares. As of July 31, 2025, approximately $311.4 million remained available under existing authorizations. In August 2025, the board authorized an additional $500 million for repurchases.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) was signed into law on July 4, 2025. Management does not expect a material impact on current year financial statements.
- Risks: Key risks include global economic conditions, currency exchange rate volatility, integration of acquisitions, and potential negative impacts from changes in trade policies and tariffs.
Investor Verification Checklist
- Divestiture Impact: Verify the final closing date and net proceeds of the medical contract manufacturing business sale expected in Q4 2025.
- Debt Servicing: Monitor the impact of rising interest rates on the $2.1 billion debt load, particularly given the 39.6% increase in Q3 interest expense.
- Organic Growth Trends: Assess the sustainability of the 14.6% organic growth in the ATS segment versus the 2.0% decline in the IPS segment.
- Share Repurchase Pace: Track the utilization of the newly authorized $500 million repurchase program announced in August 2025.
- Foreign Currency: Review the impact of currency fluctuations, which contributed to a $13 million reduction in Q3 sales compared to prior year rates.